Arlocabtagene autoleucel：一种用于重度预治疗复发/难治性多发性骨髓瘤的靶向 GPRC5D CAR-T 细胞疗法
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
97.0分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
ALL SOURCES
全部资讯 96
条件筛选 · 已选 3 项 · 共 96 条展开收起
靶点
多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
84.3分
★★★★☆
站内排序·非疗效
多发性骨髓瘤感染风险增加的免疫生物标志物
Immune biomarkers of increased infection risk in multiple myeloma.
83.9分
★★★★☆
站内排序·非疗效
多发性骨髓瘤的新型免疫靶点：生物学意义与治疗潜力
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.
69.3分
★★★☆☆
站内排序·非疗效
复发性/难治性多发性骨髓瘤伴髓外浆细胞瘤在疾病晚期成功再挑战人源化 B 细胞成熟抗原靶向 CAR-T 细胞免疫治疗：一例病例报告
Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chi
66.1分
★★★☆☆
站内排序·非疗效
双特异性抗体作为复发/难治性多发性骨髓瘤 BCMA CAR-T 细胞治疗的桥接
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.
65.9分
★★★☆☆
站内排序·非疗效
探索 BCMA/GPRC5D 后的治疗格局：塞利尼索、硼替佐米与地塞米松在五重难治性多发性骨髓瘤序贯免疫治疗失败后的疗效——多中心分析
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refrac
65.6分
★★★☆☆
站内排序·非疗效
靶向 BCMA 或 GPRC5D 的双特异性抗体在 CAR-T 细胞治疗后复发多发性骨髓瘤中高度有效
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
65.5分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤与拟态：CAR-T 细胞治疗和抗 CD38 单克隆抗体治疗后患者的胃肠道组织学表现
Multiple Myeloma and Mimicry: Gastrointestinal Tract Histologic Findings in Patients Following Chimeric Antigen Receptor T-cell Therapy and Anti-CD38
64.9分
★★★☆☆
站内排序·非疗效
FDA 批准概要：ciltacabtagene autoleucel 用于复发/难治性多发性骨髓瘤
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.
64.4分
★★★☆☆
站内排序·非疗效